The upregulation of NPY1R appears to be specific to ER+ breast cancer patients and thus, a combination of multiple markers, including NPY1R, may be required to improve the sensitivity and specificity for the detection of circulating breast cancer cells. This evidence concerns the gene ESR1 and breast carcinoma.